熱門資訊> 正文

安捷伦获得FDA批准Tecelra配套诊断产品

2024-08-03 00:46

Agilent (NYSE:A) has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx as a diagnostic tool to help identify patients who may be eligible for treatment with Adaptimmune Therapeutics’ (NASDAQ:ADAP) newly approved gene therapy Tecelra.
Adaptimmune (ADAP) announced late Thursday that it had received FDA accelerated approval for Tecelra. The product is approved for the treatment of advanced MAGE-A4 positive synovial sarcoma in adults with certain HLA types who have received prior chemotherapy.

More on Agilent Technologies

Agilent: Making A Move To Ignite Some Growth
Agilent Hit By Cyclical Headwinds, But The Growth Story Remains Intact Long Term
Agilent Technologies, Inc. (A) Jefferies 2024 Global Healthcare Conference (Transcript)
Agilent acquires Sigsense to boost AI capabilities for lab operations
Agilent to acquire North American CDMO BIOVECTRA for $925 million

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。